Oncolytic viruses (OVs) are promising therapeutic tools for solid tumors due to their many biological advantages compared to traditional approaches including: (1) the selective replication of the OVs in cancer cells without affecting normal cells; (2) the lack of resistance mechanism by the targeted cells and (3) the capacity of the OV to spread throughout the tumor once a few cells have been infected (4) the capacity to trigger an immune response against the tumors. These protocols represent a potential therapy for several tumors, including rare pediatric brain tumors, due to their capacity to target cancer stem cells (CSC) which are, in theory, the cells responsible for tumor growth.
Dr. Sabine Mueller kicked off a Phase 1 clinical trial out of the University of San Francisco using the measles virus (PNOC005). After seeing promise at the onset of the trial, the Ty Louis Campbell Foundation provided additional funding to support her continued research in partnership with Solving Kids’ Cancer. Funding was intended to help expand enrollment. Information about the ongoing clinical trial can be found at clinicaltrials.gov.
View the most recent update in Clinical Cancer Research.
